They called it the midnight elixir, though it had no name on the vial. Just a number: X-7. And a date—October 14th, 1922—that was the day James Callahan stopped being a man who worried about money and started being a man who worried about everything else.

I am writing this because I want someone to know what happened. Not the version that appeared in the New York Times, where I am either a fraud or a prophet, depending on which columnist you read. I want the truth, and the truth is this: I saved the world and ruined it in the same hour.

The elixir extended human life by approximately ten years per injection. Not forever—that was the punchline, the joke that no one found funny once they understood it. Ten years. Enough to see your children grow up. Not enough to see your grandchildren.

I was thirty-four when I first injected myself. I am writing this at forty-four, which means I have exactly ten years left. Not more, not less. The elixir was precise like that.

PART I

The laboratory was in Long Island, a converted farmhouse where I had been working with three other scientists. Dr. Yuki Tanaka handled the cellular regeneration protocols. Professor Heinrich Vogel contributed the chemical stabilization work. Dr. Catherine Reeves managed the ethical review—which is to say, she was the only one at the table who kept asking whether we should be doing this at all.

I was the project lead. I had won a Nobel for something entirely different—a theory of protein folding that had made me famous at twenty-nine and obsolete at thirty-two. The elixir was my attempt to become relevant again.

It worked on the fourth try. The fifth try confirmed it. By the sixth try, I knew I had changed the world.

The mouse lived for three years instead of two. It was a small creature. It did not seem to notice the extra time. It ate, it groomed itself, it slept. When the scientists who had not received the elixir died of natural causes, it simply kept going.

PART II

I told the investors in November. They were not scientists—they were men who wore silk ties and spoke in percentages. One of them, a banker named Prescott who smelled of cigars and impatience, asked the question that would define everything that followed: "How much does it cost to produce?"

I told him the truth: at current scale, approximately two hundred thousand dollars per dose. Enough to treat maybe five hundred people in the first year. A fraction of a percent of the population.

Prescott nodded slowly. "Then we don't publish it," he said. "We sell it."

Catherine Reeves left the project the next morning. She wrote a letter to the scientific journal Nature describing the elixir as "a solution without a problem—a medical breakthrough searching for a disease." I never received the letter. It appeared in the newspaper six months later, unsigned, and was dismissed as the ranting of a disgruntled former employee.

By December, I had made my decision. I would publish the formula. Anyone who could afford the ingredients could make the elixir for themselves. The world would decide what to do with it.

What I did not understand was that the world had already decided. It had simply not told me.

PART III

Prescott was faster than I expected. Within three weeks, he had secured contracts with three pharmaceutical companies and a government in South America that I had never heard of. Within two months, the elixir was being produced in a facility in New Jersey that I was not allowed to visit.

I watched from a distance as my creation was transformed. The price dropped from two hundred thousand to fifty thousand to twenty thousand. More people could afford it. This should have been a triumph.

But the elixir only worked on people under forty. I had not known this in the laboratory. Mouse cells behave differently than human cells, and human cells behave differently depending on how many years they have already lived.

Prescott knew. He had commissioned studies. He had known for months before I did.

I confronted him in his office on a Friday in March. He looked at me the way one looks at a child who has just discovered that Christmas is not magical. "James," he said, "do you really think we were going to give ten extra years to everyone? The world runs on succession. Kings die. Fathers die. If they don't die naturally, we find other ways. The elixir is not for everyone. It's for the people who matter."

I injected myself the next day. Not out of vanity. Out of spite. I wanted to see what he had created, and I wanted to be alive long enough to watch it crumble.

PART IV

I am forty-four. I have six years left. The elixir extended my life by exactly ten years from my original trajectory. I will die at forty-four instead of thirty-four.

Prescott is seventy-two and looks forty. He has taken the elixir every year since 1923. He will outlive everyone I know. He will outlive me.

Last week, a woman came to my office. She was thirty-eight, the maximum age for eligibility, and she was holding a check for twenty thousand dollars—half a year's salary. She wanted to know if the elixir was safe.

I told her it was. I did not tell her that I had calculated her odds of receiving it every year for the rest of her life at less than eight percent. The pharmaceutical companies were not mass-producing the elixir. They were rationing it to the people who mattered.

She left satisfied. I watched her go from my window, walking down Fifth Avenue with the purposeful stride of someone who has just purchased eternity at a discount.

I opened my notebook to a blank page and wrote: The world does not end with a bang. It ends with a price list.

And somewhere, in a laboratory I will never see, a scientist is working on version 2.0. The mice have not noticed the difference yet.

OTMES-v2-8B2D41-9.800-M8-30.0-7R0058-0.5 E_total: 9.8 | TI: 35.0 | Rank: 7 | θ: 30° M: [7.0,4.0,6.5,5.5,5.0,6.0,3.5,8.0,5.0,7.5] N: [0.65,0.35] | K: [0.55,0.45] | ζ: 0.75 | Λ: 0.68